Welcome to the e-CCO Library!

DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. Lichtenstein1, M.A. Ciorba2, G. Rogler3*, D. Quirk4, C.I. Nduaka4, R.D. Pedersen4, N. Lawendy4, G. Chan4, C. Su4, J. Panés5

Created: Thursday, 21 February 2019, 9:14 AM
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3*, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9

Created: Thursday, 21 February 2019, 9:14 AM
DOP026: Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Stallmach A.*1, Bokemeyer B.2, Axler J.3, Curtis R.4, Ehehalt R.5, Feagan B.6, Geransar P.7, James A.8, Kaviya A.9, Khalid J.M.10, Wolf D.11, Schreiber S.12

Created: Wednesday, 20 February 2019, 10:36 AM
DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Atreya*1, S. Bloom2, F. Scaldaferi3, V. Gerardi4, C. Admyre5, A. Karlsson5, T. Knittel5, J. Kowalski5, M. Lukas6, R. Löfberg7, R. Petryka8, R. Schnabel9, U. Seidler10, S. Nancey11, M. Neurath1, C. Hawkey12

Created: Friday, 22 February 2019, 9:49 AM
DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.G. Feagan1, M.C. Dubinsky2, M. Lukas3*, D. Quirk4, C.I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, W. Wang4, G. Chan4, C. Su4

Created: Thursday, 21 February 2019, 9:14 AM
DOP027: Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Wildenberg*1, A. Levin2, A. Ceroni3, Z. Guo2, F. Bloemendaal2, D. Ebner3, G. van den Brink1

Created: Friday, 22 February 2019, 9:49 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wils P.*1, Bouhnik Y.2, Michetti P.3, Flourie B.4, Brixi H.5, Bourrier A.6, Allez M.7, Duclos B.8, Serrero M.9, Buisson A.10, Amiot A.11, Fumery M.12, Roblin X.13, Peyrin-Biroulet L.14, Filippi J.15, Bouguen G.16, Abitbol V.17, Coffin B.18, Simon M.19, Laharie D.20, Pariente B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bian S.*1, Tang H.T.1, Peeters M.1, Compernolle G.1, Dreesen E.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP028: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Gecse*1, Z. Vegh1, Z. Kurti1, M. Rutka2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, P. A. Golovics1, T. Kristof6, L. Lakatos7, P. Miheller8, F. Nagy9, K. Palatka10, M. Papp11, L. Lakner12, A. Patai13, A. Salamon14, T. Szamosi3, Z. Szepes9, B. Szalay15, G. T. Toth16, A. Vincze17, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Kemp1*, L. Dibley2, U. Chauhan3, K. Greveson4, S. Jaghult5, K. Ashton6, S. Buckton7, J. Duncan8, P. Hartmann9, N. Ipenburg10, L. Moortgat11, R. Theeuwen12, M. Verway13, L. Younge14, P. Bager15

Created: Thursday, 21 February 2019, 9:14 AM
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van Stappen T.*1, Vande Casteele N.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP029: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bettey1, L. Downey1, C. Underhill1, J. Callaghan1, M. Rush2, I. Ahmed1, F. Cummings*1

Created: Friday, 22 February 2019, 9:49 AM
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Kollen1, A. Leroyer2, A. Breton3, M. Fumery4, G. Savoye5, J. Lemale6, D. Morin1, B. Pariente7, E. Mas3, D. Turck8, M. Al Khouri1, P. Blanc9, C. Gower2, G. Pineton de Chambrun9*

Created: Thursday, 21 February 2019, 9:14 AM
DOP02: Increasing incidence of Inflammatory Bowel Disease in a high prevalence country: A nationwide study in Finland
Year: 2022
Source: ECCO'22
Authors: Kontola, K.(1);Oksanen, P.(2,3);Huhtala, H.(4);Jussila, A.T.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP02: Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Grant, S.(1)*;Johnson, K.(1);Thomas, T.(2);Honig, G.(1);Bielecki, P.(1);Dendrou, C.(3);Guo, S.(1);Kulicke, R.(1);Li, P.(1);L'Italien, L.(1);Spies, N.(1);Stransky, N.(1);Uhlig, H.(4);Varma, M.(1);Travis, S.(5);Buckley, C.(2);Magram, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP02: Supplementation with butyrate producing bacteria reduces tumour load in a mouse model of colitis-associated cancer
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Montalban Arques*1, I. Olivares Rivas1, K. Atrott1, C. Gottier1, S. Lang1, G. Leventhal2, T. DeWouters3, M. Scharl1, M. Spalinger1

Created: Friday, 22 February 2019, 9:41 AM
DOP02: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis and have a homeostatic immunophenotype
Year: 2021
Source: ECCO'21 Virtual
Authors: Dart, R.(1,2);Zlatareva, I.(1,2);Irving, P.(1,3);Hayday, A.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Miyoshi1, D. Saito1, M. Nakamura2, M. Miura1, T. Mitsui1, T. Kudo3, S. Murakami3, M. Matsuura1, T. Hisamatsu1

Created: Thursday, 30 January 2020, 10:12 AM
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre “real world” study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Srinivasan A.*1, Vasudevan A.1,2,3, McFarlane A.1, Gibson P.2,3, Sparrow M.2,3, van Langenberg D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Smits*, L. Derikx, J. Drenth, D. de Jong, A. van Esch, F. Hoentjen

Created: Friday, 22 February 2019, 9:49 AM